Roberto Nieto, MD
Neurology · Mansfield, TXNPI 1750430419
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $193,421 of the $245,943 with a category attached, or 78.6%. 60 manufacturers reported payments, led by EMD Serono, Inc. at 34.9% of the total. Reporting peaked in 2019 at $73,831 and has fallen 65.8% since, to $25,254 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,487 payments — averaging $165.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$86K
- Amgen$39K
- AbbVie$37K
- Teva Pharmaceuticals USA, Inc.$17K
- Supernus Pharmaceuticals, Inc.$16K
- Axsome Therapeutics, Inc.$13K
- plus $38K from 54 others
Across 54 payments — averaging $1445.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$67K
- Novartis$3K
- UCB SA$3K
- Avanir Pharmaceuticals, Inc.$3K
- UCB, Inc.$2K
- Amgen$4
What the payments were for
- Consulting fees$11,9665%
- Speaking & faculty fees$193,42179%
- Travel & lodging$11,0364%
- Food & beverage$28,88712%
- Education$6330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$245,943 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 25 | $220,144 |
| Austedo XrDeutetrabenazine | 33 | $201,202 |
| NuplazidPimavanserin Tartrate | 29 | $194,053 |
| AustedoDeutetrabenazine | 20 | $183,817 |
| Nurtec OdtRimegepant Sulfate | 88 | $149,644 |
| BelsomraSuvorexant | 145 | $81,261 |
| NourianzIstradefylline | 31 | $76,362 |
| UbrelvyUbrogepant | 51 | $70,142 |
| CopaxoneGlatiramer Acetate | 12 | $69,984 |
| Aimovig AutoinjectorErenumab-Aooe | 56 | $57,837 |
| RytaryCarbidopa/Levodopa | 23 | $52,570 |
| Emgality PenGalcanezumab-Gnlm | 37 | $42,512 |
| VimpatLacosamide | 20 | $39,539 |
| QuliptaAtogepant | 34 | $39,364 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 40 | $33,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Copaxone | $17,466 | $455,00265 claims |
| BiogenVumerity | $1,603 | $220,14425 claims |
| Acadia Pharmaceuticals IncNuplazid | $170 | $194,05329 claims |
| PfizerNurtec Odt | $1,793 | $149,64488 claims |
| AbbVieUbrelvy, Qulipta | $36,854 | $109,50685 claims |
| MerckBelsomra | $223 | $81,261145 claims |
| Kyowa Kirin, Inc.Nourianz | $1,506 | $76,36231 claims |
| UCB, Inc.Vimpat, Briviact | $1,460 | $59,53132 claims |
| Amneal Pharmaceuticals LLCRytary | $356 | $52,57023 claims |
| SK Life Science, Inc.Xcopri | $7,334 | $29,74924 claims |
| Eisai Inc.Fycompa | $575 | $27,36923 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $190 | $22,28714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in Mansfield
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.